We also identified some mutation-associated epigenetically dysregulated genes, including REC8 and HOXA7. Together, these epigenetic signatures represent potential therapeutic targets regardless of the different types of the underlying mutations present in individual AML cases. The gene discussed is HOXA7; the disease is acute myeloid leukemia.